Journal: Stem Cell Research & Therapy

Article Title: NCAPH-YAP1 interaction promotes breast cancer stemness and tumor progression

doi: 10.1186/s13287-025-04648-0

Figure Lengend Snippet: Transcriptome sequencing analysis of BC cell lines after NCAPH overexpression. A Heatmap of DEGs following NCAPH overexpression. B GSEA analysis showing enrichment of the Hippo signaling pathway. C KEGG pathway analysis of DEGs. D KMplot database analysis of the impact of YAP1 expression levels on OS in BC patients

Article Snippet: The primary antibodies used were against NCAPH (1:5000, Cat# 67,655–1-Ig), CD133 (1:5000, Cat#18,470–1-AP), CD44 (1:5000, Cat#60,224–1-Ig), YAP1 (1:5000, Cat# 13,584–1-AP), phospho-YAP1 (Ser127, 1:5000, Cat#29,018–1-AP), OCT4 (1:5000, Cat#60,242–1-Ig), SOX2 (1:2000, Cat#66,411–1-Ig), Nanog (1:2000, Cat#67,255–1-Ig), Cyclin D1 (1:5000, Cat#26,939–1-AP), CDK1 (1:5000, Cat#67,575–1-Ig), CDK2 (1:5000, Cat#10,122–1-AP), CDK4 (1:5000, Cat#66,950–1-Ig), β-actin (1:5000, Cat#66,009–1-Ig), Flag (1:5000, Cat#66,008–4-Ig), α-Tubulin (1:5000, Cat#66,031–1-Ig), and GAPDH (1:5000, Cat#10,494–1-AP), all sourced from Proteintech (Rosemont, IL, USA).

Techniques: Sequencing, Over Expression, Expressing

Journal: Stem Cell Research & Therapy

Article Title: NCAPH-YAP1 interaction promotes breast cancer stemness and tumor progression

doi: 10.1186/s13287-025-04648-0

Figure Lengend Snippet: NCAPH interacts with YAP1 and promotes YAP1 expression and nuclear translocation. A WB analysis examining the effects of NCAPH overexpression or knockdown on Hippo-YAP1 signaling (Full-length gels are presented in Supplementary Fig. 6). B WB analysis assessing the effect of NCAPH overexpression on YAP1 nuclear translocation (Full-length gels are presented in Supplementary Fig. 7). C IF showing co-localization of NCAPH and YAP1 proteins within cells. D Co-IP assay demonstrating the interaction between NCAPH and YAP1 (Full-length gels are presented in Supplementary Fig. 7)

Article Snippet: The primary antibodies used were against NCAPH (1:5000, Cat# 67,655–1-Ig), CD133 (1:5000, Cat#18,470–1-AP), CD44 (1:5000, Cat#60,224–1-Ig), YAP1 (1:5000, Cat# 13,584–1-AP), phospho-YAP1 (Ser127, 1:5000, Cat#29,018–1-AP), OCT4 (1:5000, Cat#60,242–1-Ig), SOX2 (1:2000, Cat#66,411–1-Ig), Nanog (1:2000, Cat#67,255–1-Ig), Cyclin D1 (1:5000, Cat#26,939–1-AP), CDK1 (1:5000, Cat#67,575–1-Ig), CDK2 (1:5000, Cat#10,122–1-AP), CDK4 (1:5000, Cat#66,950–1-Ig), β-actin (1:5000, Cat#66,009–1-Ig), Flag (1:5000, Cat#66,008–4-Ig), α-Tubulin (1:5000, Cat#66,031–1-Ig), and GAPDH (1:5000, Cat#10,494–1-AP), all sourced from Proteintech (Rosemont, IL, USA).

Techniques: Expressing, Translocation Assay, Over Expression, Knockdown, Co-Immunoprecipitation Assay

Journal: Stem Cell Research & Therapy

Article Title: NCAPH-YAP1 interaction promotes breast cancer stemness and tumor progression

doi: 10.1186/s13287-025-04648-0

Figure Lengend Snippet: The YAP1 inhibitor Verteporfin reverses NCAPH overexpression-induced enhancement of CSC properties, proliferation, migration, and invasion in BC cells. A Verteporfin inhibits YAP1 expression and also reverses the increase in tumorsphere formation induced by NCAPH overexpression (Full-length gels are presented in Supplementary Fig. 8). B WB experiments show that Verteporfin reverses CSC marker protein expression induced by NCAPH overexpression (Full-length gels are presented in Supplementary Fig. 8). C The CCK-8 assay shows that Verteporfin reverses the enhanced proliferative capacity in BC cell lines induced by NCAPH overexpression. D ​The wound healing assay indicates that Verteporfin reverses the increase in migratory capacity of BC cell lines induced by NCAPH overexpression. E The Transwell assay reveals that Verteporfin markedly reverses the enhancement of migratory and invasive capabilities in BC cell lines induced by NCAPH overexpression. Data are presented as mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001)

Article Snippet: The primary antibodies used were against NCAPH (1:5000, Cat# 67,655–1-Ig), CD133 (1:5000, Cat#18,470–1-AP), CD44 (1:5000, Cat#60,224–1-Ig), YAP1 (1:5000, Cat# 13,584–1-AP), phospho-YAP1 (Ser127, 1:5000, Cat#29,018–1-AP), OCT4 (1:5000, Cat#60,242–1-Ig), SOX2 (1:2000, Cat#66,411–1-Ig), Nanog (1:2000, Cat#67,255–1-Ig), Cyclin D1 (1:5000, Cat#26,939–1-AP), CDK1 (1:5000, Cat#67,575–1-Ig), CDK2 (1:5000, Cat#10,122–1-AP), CDK4 (1:5000, Cat#66,950–1-Ig), β-actin (1:5000, Cat#66,009–1-Ig), Flag (1:5000, Cat#66,008–4-Ig), α-Tubulin (1:5000, Cat#66,031–1-Ig), and GAPDH (1:5000, Cat#10,494–1-AP), all sourced from Proteintech (Rosemont, IL, USA).

Techniques: Over Expression, Migration, Expressing, Marker, CCK-8 Assay, Wound Healing Assay, Transwell Assay